PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjcrBMJ Case ReportsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
BMJ Case Rep. 2010; 2010: bcr11.2009.2441.
Published online 2010 March 30. doi:  10.1136/bcr.11.2009.2441
PMCID: PMC3029455
Unexpected outcome (positive or negative) including adverse drug reactions

Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy

Abstract

Intravitreal bevacizumab (Avastin) has been used off label for various conditions, including proliferative sickle cell retinopathy (PSR). Some authors have reported a more rapid resolution of the vitreous haemorrhage in Goldberg stage 4 PSR. Following injection of 1.25 mg of bevacizumab in each eye in a case of PSR (right eye with stage 3 sea fan neovascularisation and left eye with organising vitreous haemorrhage), we recently found a surprising association with significant secondary hyphaema on the fifth day post injection in the eye with vitreous haemorrhage. After 4 weeks, there was a dramatic fibrotic resolution of the stage 3 sea fan in the other eye. Systemic bevacizumab as used in the management of colorectal cancer has been associated with bleeding diathesis in some cases, as well as with deep venous thrombosis. The rheological profile of bevacizumab is not clear-cut at the moment and the drug should therefore be used with caution in cases of stage 4 PSR.


Articles from BMJ Case Reports are provided here courtesy of BMJ Group